SmartDrugDiscovery
ExploreCollaboratePromote
Sign in
SmartDrugDiscovery

Precision in research — explore, collaborate, and promote across drug discovery.

AboutExploreCollaboratePromoteContact
AllPapersDatasetsToolsNewsPodcast
arrow_backAll episodes
EP 29

Cystic Fibrosis: A Blueprint for Rare Disease Cures

Cystic fibrosis was once a devastating diagnosis, but thanks to 30 years of painstaking science, bold strategy, and intense collaboration, it's now a manageable chronic condition. This episode explores the key scientists, funding models, and breakthroughs that made this transformation possible. The story of cystic fibrosis serves as a blueprint for tackling other rare diseases, with lessons on empowered patient advocacy, innovation in research tools, and sustained focus.

cystic fibrosisrare diseasegenetic diseaseprotein-fixing drugshigh-throughput screeningartificial intelligence
play_arrowListen to episode

Key Concepts

Cystic Fibrosis

  • Cystic fibrosis is a genetic disease caused by a faulty protein called CFTR.
  • The disease causes thick and sticky mucus to build up in the lungs, leading to chronic infections and respiratory failure.
  • Cystic fibrosis was once a devastating diagnosis, but new treatments have transformed it into a manageable chronic condition.

CFTR Gene

  • The CFTR gene was discovered in 1989.
  • The gene encodes a protein that moves salt and water across cell membranes.
  • Mutations in the CFTR gene cause cystic fibrosis.

Protein-Fixing Drugs

  • Protein-fixing drugs aim to rescue the faulty protein made by the CFTR gene.
  • These drugs use a small molecule to fix the protein, rather than replacing the gene.
  • The first protein-fixing drug, Caldeco, was approved in 2012.

High-Throughput Screening

  • High-throughput screening technology, such as FRET, enables the testing of millions of chemical compounds to find the ones that can fix the faulty protein.
  • This technology has been crucial in the development of protein-fixing drugs for cystic fibrosis.
  • FRET detects a light signal produced when the CFTR protein channel opens and ions flow through.

Cystic Fibrosis Foundation

  • The Cystic Fibrosis Foundation (CFF) played a crucial role in funding the search for protein-fixing drugs.
  • The CFF committed $47 million to a small biotech company called Aurora Biosciences.
  • The CFF's funding model, known as venture philanthropy, allowed them to take a strategic bet on the high-risk, high-reward search for protein-fixing drugs.

Artificial Intelligence

  • Artificial intelligence (AI) is poised to be a massive accelerator for the cystic fibrosis blueprint.
  • AI can analyze vast data sets and predict which molecules are most likely to work.
  • The combination of the cystic fibrosis blueprint and AI could compress the initial discovery phase from years to months.

Episode Summary

  • check_circleCystic fibrosis used to be a devastating diagnosis, but new treatments have transformed it into a manageable chronic condition.
  • check_circleThe median survival age for cystic fibrosis patients has increased from under 40 in 2010 to potentially living into their 80s with the newest treatments.
  • check_circleThe transformation of cystic fibrosis treatment was a result of 30 years of science, strategy, and collaboration.
  • check_circleThe discovery of the CFTR gene in 1989 was a major breakthrough, but finding the gene wasn't the same as curing the disease.
  • check_circleThe first approach to treating cystic fibrosis was gene therapy, but it failed repeatedly due to the difficulty of getting the new gene past the thick mucus and avoiding the immune system.
  • check_circleThe next approach was to fix the protein that the faulty gene was making, using a small molecule drug to rescue the protein.
  • check_circleA crucial lab finding showed that the faulty protein could be fixed at a lower temperature, suggesting that a chemical compound could act as a permanent chaperone to help it fold correctly.
  • check_circleThe Cystic Fibrosis Foundation (CFF) played a crucial role in funding the search for protein-fixing drugs, committing $47 million to a small biotech company called Aurora Biosciences.
  • check_circleThe CFF's funding model, known as venture philanthropy, allowed them to take a strategic bet on the high-risk, high-reward search for protein-fixing drugs.
  • check_circleThe development of high-throughput screening technology, such as FRET, enabled the testing of millions of chemical compounds to find the ones that could fix the faulty protein.

Full Transcript

Discussion

Join the discussion — sign in to leave a comment.

Log in to comment
biotech

Live Literature

Current papers related to this episode's topics.

podcasts

Related Episodes

  • check_circleThe first breakthrough drug, Caldeco, was approved in 2012, but it only worked for a small percentage of patients with a specific type of mutation.
  • check_circleCombination therapies, such as Orkambi and Simdeco, were developed to treat more patients, but they were not perfect cures.
  • check_circleThe triple combination therapy, Trikafta, was approved in 2019 and has had a significant impact on patients, with a 14% absolute improvement in lung function and 60% fewer severe lung infections.
  • check_circleThe development of Trikafta was a result of a bold clinical gamble by Vertex, which ran multiple large clinical trials in parallel to shave years off the development timeline.
  • check_circleThe success of Trikafta has changed the trajectory of the disease for many patients, with some experiencing a 'purge' of thick mucus from their lungs and regaining senses such as smell.
  • check_circleThe key lessons from the cystic fibrosis blueprint include empowered patient advocacy, innovation in research tools, and sustained focus.
  • check_circleArtificial intelligence (AI) is poised to be a massive accelerator for the cystic fibrosis blueprint, enabling the analysis of vast data sets and prediction of which molecules are most likely to work.
  • check_circleThe combination of the cystic fibrosis blueprint and AI could compress the initial discovery phase from years to months, potentially transforming other rare diseases in a decade or less.